Used in scans for cognitive impairment. Sold as Tauvid. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Flortaucipir F-18 (sold as Tauvid), first approved May 28, 2020, with 0 new uses approved and 0 published complete response letters.
| A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer Disease · Eli Lilly and Company | Phase 1 | Recruiting | Mar 7, 2024 |
| Alzheimer's Disease Neuroimaging Initiative 4Mild Cognitive Impairment, Alzheimer Disease · University of Southern California | — | Enrolling by invitation | Nov 15, 2022 |
| Depression and DrivingDepression, Drive · Washington University School of Medicine | — | Recruiting | Jul 7, 2022 |
| Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)Alzheimer Disease · Tammie L. S. Benzinger, MD, PhD | — | Recruiting | Oct 8, 2020 |
| NFL LONG Prospective StudyConcussion, Brain · University of North Carolina, Chapel Hill | Phase 1 | Active, not recruiting | Feb 10, 2020 |
| Longitudinal Early-onset Alzheimer's Disease Study ProtocolEarly Onset Alzheimer Disease, Alzheimer Disease · Indiana University | — | Active, not recruiting | Apr 25, 2018 |
| F 18 T807 Tau PET Imaging of Alzheimer's DiseaseAlzheimer Disease · Tammie L. S. Benzinger, MD, PhD | — | Recruiting | Apr 10, 2015 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 28, 2020 | TauvidNDA 212123 · New molecular entity | Avid Radiopharms Inc | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
